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Atherosclerosisa b s t r a c t
A number of studies have reported an association between increased levels of antibodies against
oxidized low-density lipoprotein (oxLDL) and cardiovascular disease, but the anti-oxLDL antibody
has not been confirmed to serve as an effective biomarker for prediction of acute myocardial
infarction (AMI). Apolipoprotein B100 (ApoB100)-derived peptide fragments generated by proteolytic
degradation and aldehyde modification are the major antigens in oxLDL, and so the present work
was undertaken to detect circulating IgG for Apo-B100-derived peptide antigens. An in-house
enzyme-linked immunosorbent assay (ELISA) was developed with eight ApoB100-derived peptide
antigens (Ag1–Ag8) to detect circulating anti-ApoB100 IgG levels in 267 patients with AMI and 201
control subjects. Binary logistic regression analysis revealed that circulating IgG for Ag1 was
significantly higher in the patient group than the control group (P < 0.001) after adjustment for
age, gender, smoking, hypertension, diabetes and circulating levels of cholesterol, HDL, LDL, ApoA
and ApoB100. None of the other seven antigens detected an increase in IgG levels in AMI patients
compared with control subjects. Spearman correlation analysis showed no correlation between
IgG antibody for Ag1 and clinical characteristics. In conclusion, the linear peptide antigens derived
from ApoB100 may be suitable for the development of an ELISA antibody test for prediction of AMI,
although further confirmation is still needed in large-scale clinical studies.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction [30]. AMI is the leading cause of death in coronary heartAcute myocardial infarction (AMI) is defined as myocardial cell
death due to prolonged ischemia [14], characterized mainly by
rupture or erosion of coronary atherosclerotic plaque and subse-
quent complete or incomplete occlusive thrombosis. Patients can
be diagnosed as having AMI when they have increased blood con-
centrations of sensitive and specific biomarkers, such as circulating
troponin or the membrane-bound fraction of creatinine kinasedisease, but there are still no effective biomarkers available for
prediction of AMI or identification of unstable coronary plaques.
Atherosclerosis of coronary arteries is the main cause of AMI.
Sub-endothelial retention of low-density lipoprotein (LDL) on
account of accumulation of the oxidized form of LDL (oxLDL) in
macrophages and formation of foam cells as a critical early event
in atherogenesis [10,17]. Many immunocytochemical studies have
identified both oxLDL epitopes and anti-oxLDL immunoglobulins
within atherosclerotic lesions [36]. Normal levels of oxLDL are as
low as 0.1 ng/lg LDL protein in healthy people [13], making
measurement difficult. In addition, spot oxLDL measurements only
provide a snap-shot of concentration at a particular moment and
are likely to be susceptible to extraneous factors, including diet,
smoking and exercise. However, the oxidative modification of
LDL leads to the formation of immunogenic epitopes that can
induce the secretion of specific antibodies against oxLDL [29,1].
Circulating antibodies against oxLDL represent a durable measure
of lipid peroxidation [21].
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can be detected almost in every individual, and the concentrations
of anti-oxLDL antibodies often peak just before the onset of clinical
disease [32]. There are numerous studies demonstrating the asso-
ciation between circulating anti-oxLDL antibodies and cardiovas-
cular disease, but the results reported to date have been
inconsistent. Some studies have determined a positive correlation
between the levels of circulating anti-oxLDL antibodies and
atherosclerotic diseases, whereas others have shown an opposite
result [3,12,11,33,16,2,34]. The reasons for inconsistent findings
may be due to the difficulties in standardizing the LDL antigens
used for testing of antibodies to oxLDL, which can also be altered
on account of oxidation ex vivo [11,20]. An approach to overcome
the problem of standardization is to detect antibodies against
specific native or MDA-modified ApoB100 peptide sequences
[5,4,19].
ApoB100 is the only component permanently associated with
formation of LDL in the body. Its peptide fragments generated by
the proteolytic degradation and aldehyde-modification are the
major antigens in oxLDL [25]. These antigens have the advantage
of being specific to oxLDL for the unique amino acid sequence.
The mature ApoB100 protein is composed of 4563 amino acids in
a single polypeptide chain that may carry many human leukocyte
antigen (HLA)-restricted epitopes. The present work was thus
undertaken to develop an in-house enzyme-linked immunosor-
bent assay (ELISA) with ApoB100-derived linear peptide antigens




A total of 267 patients who were diagnosed with AMI between
January 2012 and January 2014 were recruited by the Department
of Cardiovascular Medicine, Fourth Affiliated Hospital of China
Medical University, Shenyang, China. Of these 267 patients aged
60.89 ± 11.01 years, 200 were male and 67 were female. They were
all diagnosed with spontaneous AMI (namely type 1) based on the
Third Universal Definition of Myocardial Infarction published by
the European Society of Cardiology [31], including both ST eleva-
tion myocardial infarction and non-ST-elevation myocardial infarc-
tion, one of whom had atrial septal defect without any symptomTable 1
Clinical characteristics of patients with AMI and control subjects.
Characteristics AMI (n = 267) Control (n = 201) P value
Sex (Male) 200 (74.9%) 136 (67.7%) 0.085
Age (years) 60.9 ± 11.0 59.4 ± 5.4 0.086
Smoker (%) 160 (59.9%) 67 (37.4%) <0.001
Drinker (%) 77 (28.8%) 42 (21.1%) 0.072
Hypertension (%) 138 (51.7) 46 (22.9%) <0.001
Diabetes (%) 71 (26.6%) 30 (15.1%) 0.004
Obesity (%) 39 (17.3%) 38 (19.0%) 0.666
SBP (mmHg) 129.2 ± 22.9 130.9 ± 18.1 0.400
DBP (mmHg) 77.5 ± 14.5 78.4 ± 10.8 0.484
Heart rate (ppm) 73.2 ± 15.8 76.2 ± 11.6 0.021
BMI 24.7 ± 3.7 25.3 ± 3.1 0.083
Cholesterol (mM) 4.50 ± 1.09 5.27 ± 0.97 <0.001
Triglyceride (mM) 1.69 ± 1.28 1.91 ± 1.92 0.153
HDL (mM) 1.01 ± 0.25 1.29 ± 0.33 <0.001
LDL (mM) 3.02 ± 0.96 3.13 ± 0.81 0.242
ApoA (mM) 0.92 ± 0.43 1.34 ± 0.22 <0.001
ApoB (mM) 0.73 ± 0.38 0.91 ± 0.18 <0.001
Gensini score 55.2 ± 26.7 –
Abbreviation: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body
mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA,
apolipoprotein A; ApoB, apolipoprotein B.and treatment. All patients who had coronary imaging data under-
went assessment for the severity of coronary heart disease by cal-
culating the Gensini score of the coronary lesions [7]. Blood
samples were taken from each patient within 24 h of the onset of
AMI. Two hundred and one healthy subjects aged
59.44 ± 5.43 years were also recruited as controls from local com-
munities, of whom 136 were male and 65 were female. Clinical
interview and biomarker detection were applied to rule out those
subjects who had history of AMI and other atherosclerotic cardio-
vascular diseases. The subjects who had malignant tumor(s), rheu-
matic and connective tissue diseases, organ transplantation or
were long-term recipients of immunosuppressive drugs were
excluded from this study. The main clinical characteristics of these
subjects are listed in Table 1. All subjects were of Chinese Han ori-
gin and all gave written consent to participate in this study as
approved by the Ethics Committee of the Fourth Affiliated Hospital
of China Medical University and conformed to the requirements of
the Declaration of Helsinki.
2.2. Autoantibody testing
Eight human ApoB100-derived peptide antigens (hAgs) were
designed, based on the computational prediction of HLA-II
restricted epitopes, 6 of which have been used in our previous
study [37]. A control antigen (cAg) was also designed based on a
maize protein (NCBI accession 1BFA_A). Information of these 9
peptide antigens is detailed in Table 2. An in-house ELISA test for
the detection of circulating IgG antibodies to ApoB100 was per-
formed as described in our previous study [37]. In brief, Corning
96-Well Microtiter EIA Plates (ImmunoChemistry Technologies,
USA) were half-coated in 0.1 ml/well of each hAg and half-coated
in 0.1 ml/well cAg. After overnight incubation at 4 C,
antigen-coated plates were washed three times with wash buffer
(PBS containing 0.1% Tween-20), 100 ll serum sample diluted
1:150 in assay buffer (DS98200, Life Technologies) was added to
each sample well and 100 ll assay buffer was also added to the
negative control (NC) wells. Following 1.5 h incubation at room
temperature, the plate was washed three times and 100 ll
peroxidase-conjugated goat antibody to human IgG (A8667,
Sigma–Aldrich) diluted 1:30,000 in wash buffer was added to each
well. After incubation at room temperature for an hour, color
development was initiated by adding 100 ll Stabilized Chromogen
(SB02, Life Technologies) and terminated 20 min later by adding
50 ll of stop solution (SS04, Life Technologies). The measurement
of optical density (OD) was performed on a microplate reader
within 10 min at 450 nm with a reference wavelength of 620 nm.
Each sample was tested in duplicate. To reduce the interference
from a nonspecific signal produced by passive absorption of
various IgG antibodies in serum to the surface of 96-well
microplate, a specific binding index (SBI) was used to express the
levels of circulating antibodies to these 8 hAgs. SBI was calculated
as follows: SBI = (ODhAg  ODNC)/(ODcAg  ODNC).
Table 2
Apo-B derived peptide antigens used.











Abbreviation: Ag, antigen; cAg, control antigen from a maize protein.
Table 4
Inter-assay deviation between plates tested.
Antigen Number of plates Mean ± SD CV (%)
Ag1 38 0.738 ± 0.074 10.03
Ag2 36 2.101 ± 0.279 13.28
Ag3 38 0.879 ± 0.057 6.48
Ag4 37 0.905 ± 0.082 9.06
Ag5 37 0.884 ± 0.122 13.80
Ag6 35 0.708 ± 0.115 16.24
Ag7 38 0.889 ± 0.101 11.36
Ag8 34 0.723 ± 0.052 7.19
Table 5
Spearman correlation between levels of IgG for Ag1 and clinical characteristics.
Patients Control
N r P N r P
Age 261 0.065 0.295 189 0.141 0.053
SBP 261 0.072 0.246 171 0.104 0.177
DBP 261 0.009 0.891 171 0.058 0.450
Heart rate 261 0.031 0.617 171 0.061 0.431
BMI 221 0.118 0.081 171 0.068 0.377
CHOL 249 0.067 0.294 171 0.064 0.409
TG 249 0.102 0.107 171 0.048 0.53
HDL 249 0.076 0.23 171 0.007 0.93
LDL 249 0.029 0.645 170 0.096 0.212
Apo-A 234 0.087 0.187 171 0.016 0.837
Apo-B 234 0.075 0.251 170 0.107 0.165
Gensini score 226 0.032 0.629
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All antibody testing data were expressed as mean ± standard
deviation (SD). Student’s t-test was initially applied to detect the
differences in SBI between the patient group and the control group;
binary logistic regression was then used to analyze the differences
in antibody levels for an antigen of interest between the patient
group and the control group, with adjustment for multiple poten-
tial confounders listed in Table 1. Spearman correlation analysis
was used to test the correlation between the anti-ApoB100 IgG
levels and clinical characteristics. Because eight antigens were
used to develop the in-house antibody testing, the significance
level was set at P = 0.006. To minimize intra-assay deviation, the
ratio of the difference between duplicate sample OD values to their
sum was used to assess the assay accuracy. If the ratio was found
to be >15% for a given sample, the test for that sample was consid-
ered to be invalid and the test was repeated. The inter-assay devi-
ation that represents the reproducibility of the in-house ELISA test
was estimated using SBI tested with pooled serum samples,
namely quality control (QC) samples that were randomly collected
from 100 healthy subjects and tested on every 96-well plate. The
coefficient of variation (CV) from the test of QC samples was then
worked out based on their mean SBI and SD. The in-house ELISA
test was considered as being repeatable when CV <20%.
3. Results
As shown in Table 1, there was no significant difference in gen-
der, age, alcohol consumption, obesity, triglyceride levels or LDL
between patients with AMI and control subjects. However, AMI
patients were more likely to have high rates of smoking, hyperten-
sion and diabetes than controls, but lower heart rate, serum
cholesterol, high density lipoprotein (HDL), ApoA and ApoB
(Table 1).
Of these eight antigens used in this study, circulating IgG for
Ag1 was significantly higher in AMI patients than control subjects
(P < 0.001, adjusted for age, gender, heart rates, smoking, hyperten-
sion, diabetes and circulating levels of cholesterol, HDL, LDL, ApoA
and ApoB). Increased IgG levels were not detected for any of the
other seven antigens in patients with AMI as compared with con-
trol subjects (Table 3).
Analysis of QC samples showed that the inter-assay deviation
was less than 20% for all eight individual antibody tests (Table 4).
Spearman correlation analysis showed no correlation between IgG
antibody for Ag1 and clinical characteristics (Table 5).
4. Discussion
There are differences in many clinical characteristics between
AMI patients and control subjects. For example, the incidence of
smoking, hypertension and diabetes are significantly higher inTable 3
The levels of anti-Apo-B IgG antibodies in the circulation.
Antigen Patients (SBI) Control (SBI) P
Ag1 0.800 ± 0.148 0.744 ± 0.140 <0.001a
Ag2 2.164 ± 0.661 2.087 ± 0.691 0.231
Ag3 0.944 ± 0.147 0.958 ± 0.218 0.526
Ag4 0.923 ± 0.142 0.889 ± 0.133 0.034
Ag5 0.889 ± 0.177 0.926 ± 0.215 0.064
Ag6 0.702 ± 0.151 0.686 ± 0.166 0.345
Ag7 0.913 ± 0.163 0.921 ± 0.174 0.639
Ag8 0.702 ± 0.176 0.696 ± 0.124 0.768
Values are presented as mean ± SD in SBI.
a P < 0.001 after adjustment for age, gender, smoking, hypertension, diabetes and
circulating levels of cholesterol, HDL, LDL, ApoA and ApoB.the patient group than the control group, all of which have been
recognized as traditional risk factors of AMI for several decades
[38]. Heart rate, serum cholesterol, HDL, ApoA and ApoB are signif-
icantly lower in AMI patients than control subjects (Table 1), which
may be caused by the characteristics of the disease and the admin-
istration of b-blockers and statins. However, no correlation
between anti-ApoB100 IgG levels and clinical characteristics was
found (Table 5), suggesting that the IgG antibody levels are inde-
pendent of the clinical states.
Circulating antibodies to oxLDL and ApoB100 have been studied
for many years in coronary heart disease and other atherosclerotic
diseases [28,24,23,15,22,8]. The increased levels of circulating anti-
bodies to oxLDL promote the formation of immune complexes with
oxLDL, which could adhere to the artery intima and cause damages
to the endothelium [35]. It has been shown that increased levels of
circulating antibodies to oxLDL may be regarded as predictors of
atherosclerosis and ACS [18], while the highest anti-oxLDL IgG
levels were observed in patients with multi-vessel CAD [9]. In fact,
increased anti-oxLDL antibody levels appear to be pathological and
may damage the walls of blood vessels, leading to atherosclerotic
changes [9] and instability of atherosclerotic plaques [16]. The
association between anti-oxLDL antibodies and cardiovascular dis-
eases has been found to be inconsistent across studies, most of
which have used the whole molecule of oxLDL as antigens so that
the outcome may not be accurate. Recently, some studies have pri-
marily used the p45 (amino acids 661–680) and p210 (amino acids
3136–3155) ApoB100 peptides to explore the mechanism of
immune response [28,24,23,15,22,8] and the development of
immune-modulatory therapies [26]. An inverse association has
been found between the levels of antibodies against these ApoB100
peptides and the severity of atherosclerosis. It has been reported
that AMI patients had lower anti-ApoB antibody levels than control
subjects matched for age and sex [6,27,4], but these studies were
all for immune-modulatory therapies but not for diagnosis.
In this study, we found that only IgG antibodies to the Ag1
sequence derived from ApoB100 were significantly increased in
patients with AMI (Table 3). Failure to show an increase in the
levels of IgG antibodies to the other ApoB100-derived antigens sug-
X. Zhang et al. / FEBS Open Bio 5 (2015) 712–716 715gests that HLA-restriction may be involved in influencing the
humoral immune response in AMI. Interestingly, the increased
levels of anti-Ag1 IgG observed in AMI patients were not correlated
with their clinical characteristics and the severity of coronary pla-
ques characterized by the Gensini score (Table 5). Possibly, the lin-
ear peptide antigen derived from ApoB100 is more suitable for the
development of a diagnostic tool for AMI than the whole oxLDL
molecule, although further screening is needed to identify more
such peptide antigens present in the ApoB100 protein. Testing of
circulating antibodies to linear antigens derived from ApoB100
may have a potential benefit for diagnosis and prognosis of AMI.
5. Conclusion
The linear peptide antigens derived from ApoB100 may be suit-
able for the development of an ELISA antibody test for prediction of
AMI, although further confirmation is still needed in large-scale
clinical studies.
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